Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
NEW YORK, Sept. 12, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Endo International plc ("Endo") (NASDAQ:ENDP) securities between November 30, 2012 and July 6, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/endo-international-plc?wire=3. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/endo-international-plc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
